Core Viewpoint - Sanxin Medical has achieved significant growth and transformation over the past decade, marking its 10th anniversary since its IPO on the Shenzhen Stock Exchange, with a strategic shift from traditional infusion and injection to blood purification, leading to a substantial increase in revenue from blood purification products [1][2]. Financial Performance - Total revenue increased from 312 million yuan in 2015 to 1.5 billion yuan in 2024, with a compound annual growth rate (CAGR) of 19.07% [2]. - Net profit attributable to shareholders rose from 52 million yuan in 2015 to 227 million yuan in 2024, with a CAGR of 17.85% [2]. - In the last five years, revenue and net profit CAGR reached 15.76% and 29.82%, respectively [2]. Profitability and Returns - The company's gross profit margin reached a record high of 35.33% in 2024 [5]. - By the end of 2024, net assets totaled 1.324 billion yuan, a 4.3-fold increase compared to ten years ago [5]. - Sanxin Medical has distributed cash dividends 11 times since its IPO, totaling 495 million yuan, which is 2.15 times the net amount raised during the IPO; the dividend for 2024 amounted to 156 million yuan, with a payout ratio of 68.77% and an annual dividend yield of 4.17% [5]. Strategic Initiatives - The company is focusing on product innovation and capitalizing on national procurement opportunities while breaking into overseas markets to expand its domestic and international market share [5]. - Sanxin Medical has initiated a global expansion strategy, successfully registering products in countries such as Indonesia, Peru, and Mexico, and is advancing certification processes in Russia and Turkey [5].

证券代码：300453 证券简称：三鑫医疗 公告编号：2025-029 为进一步加强与投资者的互动交流，江西三鑫医疗科技股份有限公司（以下简 称"公司"）将参加由江西省上市公司协会举办的"2025 年江西辖区上市公司投资 者网上集体接待日活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行,投资者可以登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2025 年 5 月 21 日（周三）15:30-17:00。 届时公司董事长彭义兴先生，董事、副总裁、董事会秘书、代理财务总监刘明 先生将在线就公司 2024 年度业绩、公司治理、发展战略、经营状况、融资计划、股 权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流。 欢迎广大投资者踊跃参与！ 特此公告。 江西三鑫医疗科技股份有限公司 关于参加江西辖区上市公司2025年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 江西三鑫医疗科技股份有限公司董事会 2025年5月16日 ...

Company Overview - Jiangxi Sanxin Medical Technology Co., Ltd. specializes in the research, manufacturing, sales, and service of medical devices, with key products including blood purification devices, drug delivery instruments, and thoracic surgery products [2] - As of the end of 2024, the company holds 203 authorized patents, 121 pending patents, and has published 26 papers, demonstrating a strong commitment to technological innovation and R&D [2] Financial Performance - For Q1 2025, the company reported revenue of 361 million yuan, an increase of 8.88% year-on-year, and a net profit of 53.73 million yuan, reflecting a slight increase of 0.20% year-on-year [2] - The gross profit margin for the same period was 34.62% [2] Market Position - As of May 6, the company's stock closed at 8.02 yuan, with a PE ratio of 18.42, significantly lower than the industry average of 48.90 and the median of 36.41 [1][3] - The total market capitalization of the company is 4.19 billion yuan [1] Institutional Holdings - As of Q1 2025, six institutions hold shares in the company, including four funds and two insurance companies, with a total holding of 14.61 million shares valued at 115 million yuan [1]

Group 1: Procurement Policy and Market Dynamics - The focus of the procurement policy has shifted from "expanding coverage and reducing prices" to "stabilizing prices and improving quality" as stated in the 2023 Government Work Report [2] - The blood dialysis consumables alliance has expanded to cover 23 provinces by 2024, indicating a nationwide implementation of procurement [2] - The company has successfully bid for all major products within the procurement scope, ensuring a competitive pricing advantage [2][3] Group 2: International Business Development - In 2024, the company's overseas business generated revenue of 27,412.03 million yuan, a year-on-year increase of approximately 40%, with blood purification product revenue growing by about 67% [4] - The company has registered blood purification products in Indonesia, Peru, and Mexico, and is accelerating certification processes in Russia and Turkey [4] - Future plans include expanding the self-certification scope in emerging markets such as Southeast Asia, South America, and Africa [4] Group 3: Market Share and Product Development - The company holds a leading market share in dialysis concentrate (powder) products, with production bases established in Jiangxi, Yunnan, Sichuan, and Heilongjiang [5] - A new production line for dialysis concentrate with a capacity of 30 million patient doses is being developed in Jiangxi, further solidifying the company's industry position [5] - The market for blood dialysis equipment has significant potential for domestic replacement, with the company's sales increasing by over 100% year-on-year in 2024 [6] Group 4: Future Outlook and Strategic Initiatives - The company is focused on innovating and upgrading blood dialysis products and expanding into various renal management areas, including diabetes and early-stage kidney disease [7][8] - The company aims to enhance its product offerings and commercialize new products to improve operational performance [8] - The procurement policy's emphasis on quality will create higher demands for product supply capabilities, benefiting leading enterprises in the industry [8]

证券代码：300453 证券简称：三鑫医疗 公告编号：2025-028 江西三鑫医疗科技股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、江西三鑫医疗科技股份有限公司（以下简称"公司"或"本公司"）回 购专用证券账户中的股份 160,000 股不参与本次权益分派。公司 2024 年年度权 益分派方案为：以公司现有总股本剔除回购专用证券账户中的股份 160,000 股后 的 522,237,525 股为基数，向全体股东每 10 股派发 2.00 元（含税）人民币现金， 实际派发现金分红总额 104,447,505 元（含税）。 2、本次权益分派实施后计算除权除息价格时，按总股本（含回购股份）折 算的每 10 股现金红利（含税）=现金分红总额/总股本*10=104,447,505 元 /522,397,525*10=1.999387 元（保留六位小数，最后一位直接截取，不四舍五入）。 本次权益分派实施后除权除息参考价=除权除息日前一日收盘价-按总股本折算 每股现金红利（含税）=除权除息日前一日收盘价-0.19 ...

Core Viewpoint - Sanxin Medical reported steady revenue growth in Q1 2025, with a focus on expanding both domestic and international markets [1][2] Financial Performance - The company achieved operating revenue of 361 million yuan, representing a year-on-year increase of 8.88% [1] - Net profit attributable to shareholders was 53.73 million yuan, slightly up by 0.20% year-on-year [1] - Deducting non-recurring items, net profit was 50.50 million yuan, showing a year-on-year growth of 7.93% [1] - Operating cash flow reached 56.67 million yuan, marking a significant increase of 60.02% year-on-year [1] - The net profit cash ratio stood at 105.48%, indicating high profitability quality [1] R&D Investment - The company increased its R&D expenditure to 16.25 million yuan, a year-on-year rise of 33.96%, supporting high-quality development [1] Domestic Market Expansion - Sanxin Medical's key blood dialysis products were selected for bulk procurement in 23 provinces and the Beijing-Tianjin-Hebei region, enhancing market share [2] - The company has gained procurement volume and is eligible for additional distribution of unallocated procurement quantities, improving competitive pricing [2] - The bulk procurement agreements are set for a duration of one year or more, ensuring stable sales channels for the company [2] International Market Strategy - The company focuses on emerging markets in Southeast Asia, South America, and Africa, with minimal exports to the U.S. [2] - In 2024, exports to the U.S. accounted for only 0.43% of total revenue [2] - Sanxin Medical has successfully registered in Indonesia, Peru, and Mexico, and is advancing certification in Russia and Turkey [2] - The establishment of a global self-certification system aims to strengthen the company's international market presence and enhance global competitiveness [2]

| 名称 | 持有数量(万股) | 占总股本比例 | 增减情况(万 | | --- | --- | --- | --- | | | | (%) | 股) | | 彭义兴 | 3223.15 | 9.04 | 不变 | | 万小平 | 1655.98 | 4.64 | -39.51 | | 前海人寿保险股份有限公司-分红保险产品华泰组 | | | | | 合 | 994.47 | 2.79 | 150.00 | | 吴江浩 | 690.00 | 1.94 | 8.00 | | 雷凤莲 | 678.01 | 1.90 | 不变 | | 彭海波 | 620.72 | 1.74 | 不变 | | 赵阳民 | 444.00 | 1.25 | 不变 | | 前海人寿保险股份有限公司-分红保险产品 | 442.62 | 1.24 | -135.01 | | 徐国涛 | 440.42 | 1.24 | 0.05 | | 张幼珍 | 345.30 | 0.97 | 新进 | | 较上个报告期退出前十大股东有 | | | | | 工银医药健康股票A | 359.10 | 1.01 | 退出 | 一、主要会计数据和财务指标 三、分 ...

证券代码：300453 证券简称：三鑫医疗 公告编号：2025-026 江西三鑫医疗科技股份有限公司 2025年第一季度报告披露的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示：江西三鑫医疗科技股份有限公司（以下简称"公司"）2025 年 第一季度报告全文于 2025 年 4 月 28 日在中国证监会指定的创业板信息披露网站 上披露，请投资者注意查阅！ 2025 年 4 月 25 日，公司召开了第五届董事会第十九次会议、第五届监事会 第十八次会议，审议通过了《关于公司<2025 年第一季度报告>的议案》。 为使投资者全面了解本公司的财务状况、经营成果等，公司《2025 年第一 季度报告》于 2025 年 4 月 28 日在中国证监会指定的创业板信息披露网站巨潮资 讯网（http://www.cninfo.com.cn）披露。 敬请投资者注意查阅。 特此公告 江西三鑫医疗科技股份有限公司董事会 2025 年 4 月 28 日 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 360,576,957.37, representing an increase of 8.88% compared to CNY 331,158,893.25 in the same period last year[4]. - Net profit attributable to shareholders was CNY 53,725,693.38, a slight increase of 0.20% from CNY 53,618,659.09 year-on-year[4]. - Total operating revenue increased to ¥360,576,957.37, up from ¥331,158,893.25, representing a growth of approximately 8.5% year-over-year[22]. - Net profit for the period reached ¥59,375,245.52, an increase from ¥57,670,378.97, marking a growth of approximately 2.9% year-over-year[23]. - Earnings per share (EPS) remained stable at ¥0.1028, slightly down from ¥0.1032 in the previous period[23]. Cash Flow and Liquidity - The net cash flow from operating activities increased by 60.02%, reaching CNY 56,670,598.77 compared to CNY 35,414,525.27 in the previous year[4]. - Cash inflow from operating activities totaled $378,004,808.23, slightly up from $369,431,494.32, indicating a 1.5% increase[25]. - Cash outflow from operating activities decreased to $321,334,209.46 from $334,016,969.05, a reduction of 3.5%[25]. - The ending cash and cash equivalents balance was $168,764,917.83, down from $174,641,673.04, a decrease of 3.4%[26]. - Cash received from sales of goods and services increased to $373,086,726.93 from $322,832,328.92, a growth of 15.6%[25]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,226,905,231.37, reflecting a 0.19% increase from CNY 2,222,709,961.44 at the end of the previous year[4]. - Total liabilities decreased to ¥753,432,626.53 from ¥814,055,748.31, indicating a reduction of approximately 7.4%[21]. - Non-current assets totaled ¥1,418,086,258.51, up from ¥1,398,754,616.01, showing an increase of about 1.0%[21]. Research and Development - Research and development expenses rose by 33.96% to CNY 16,250,108.87, primarily due to increased costs associated with ongoing R&D projects[8]. - Research and development expenses increased to ¥16,250,108.87 from ¥12,130,470.58, reflecting a commitment to innovation[22]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 18,367[11]. - The company has a total of 165,183,790 shares under lock-up agreements, with key shareholders including 彭义兴 and 雷凤莲, who hold significant portions of the shares[14]. - The company has not reported any changes in the number of restricted shares during the current period[14]. Financial Strategy and Outlook - The company reported a significant increase in financial expenses, which decreased by 58.83% to CNY -406,230.69 due to reduced interest income from time deposits[8]. - The company maintains a strong position with a significant amount of trading financial assets, which may indicate a strategic focus on liquidity management[19]. - The company plans to focus on expanding its market presence and investing in new technologies to drive future growth[24]. - The company has not disclosed any new product developments or market expansion strategies in the current report[17]. - There are no indications of mergers or acquisitions in the recent financial disclosures[17].

证券代码：300453 证券简称：三鑫医疗 公告编号：2025-025 江西三鑫医疗科技股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在否决议案的情况。 2、本次股东大会不存在变更以往股东大会已通过的决议的情况。 通过深圳证券交易所互联网系统投票的时间为2025年4月25日上午9:15至下 午15:00的任意时间。 2、现场会议召开地点：江西省南昌县小蓝经济开发区富山大道999号江西三 鑫医疗科技股份有限公司二楼会议室 3、召开方式：现场表决与网络投票相结合的方式 4、会议召集人：公司董事会 5、现场会议主持人：董事长彭义兴先生 一、会议召开和出席情况 （一）会议召开情况 1、召开时间： （1）现场会议召开时间为：2025 年 4 月 25 日下午 14:30 （2）网络投票时间为： 通过深圳证券交易所交易系统进行网络投票的时间为2025年4月25日上午 9:15-9:25，9:30-11:30，下午13:00-15:00； 6、股权登记日：2025年4月21日 本次股东大会的召开符合 ...